The Importance of Early Diagnosis and Management of Acute Heart Failure (AHF)

This section presents a concise, high-yield summary of the video’s core content, designed as a quick reference for Healthcare Professionals (HCPs).

Note: This content was developed by our editorial team based on the session transcript and slide material and was not reviewed or endorsed by the speaker.

Q1. Why is diagnosing acute heart failure based on clinical features alone challenging?

Symptoms and signs of heart failure can be non-specific, subtle, or overlap with non-cardiac conditions. While some features are classic, many patients present with atypical or less specific findings, making diagnosis uncertain. This variability increases the risk of misdiagnosis and delayed treatment when clinical judgment is used in isolation.[5,6,7] 

Q2. How does NT-proBNP improve the diagnosis of acute heart failure?

NT-proBNP provides an objective biochemical measure of cardiac stress that complements clinical assessment. When added to symptoms and signs, it significantly improves diagnostic accuracy. Normal NT-proBNP values effectively exclude heart failure, while elevated levels support the diagnosis and prompt further cardiac evaluation. [1] 

Q3. In which clinical settings is NT-proBNP most useful?

NT-proBNP is useful across the entire care pathway:

• In the community and outpatient setting, it supports early diagnosis and improves prognosis through timely referral.
• In the emergency department, it aids rapid differentiation of cardiac versus non-cardiac dyspnoea.
• In hospitalised AHF patients, it assists with risk stratification, monitoring response to therapy, and discharge planning. [8]

Q4. How should NT-proBNP cut-off values be interpreted?

NT-proBNP thresholds differ by setting and patient characteristics. Lower cut-offs are used to rule out HF in outpatients, while higher values are expected in emergency and hospitalised AHF settings. Values also increase with age. Interpretation must therefore consider clinical context rather than relying on a single universal cut-off. [9] 

Q5. What do persistently elevated or rising NT-proBNP levels indicate?

Continued elevation or a rising NT-proBNP trajectory suggests ongoing ventricular strain, residual congestion, or inadequate response to therapy. Such findings should prompt reassessment of diuretic adequacy and optimisation of guideline-directed medical therapy. [10] 

Q6. What is the clinical significance of decreasing NT-proBNP levels?

A fall in NT-proBNP reflects effective decongestion and improved haemodynamics in response to treatment. Serial reductions are associated with better short- and long-term outcomes and support continuation or cautious up-titration of disease-modifying therapy.[10] 

Q7. How does NT-proBNP guide prognosis and post-discharge care?

NT-proBNP trends during hospitalisation help define disease trajectory and establish post-discharge risk. Higher discharge values identify patients at increased risk of readmission or mortality, supporting closer follow-up and earlier intensification of therapy after discharge. [11] 

Q8. What role does NT-proBNP play in guiding GDMT in acute heart failure?

NT-proBNP helps clinicians decide when to prioritise decongestion versus intensification of GDMT. Rather than relying solely on symptoms or blood pressure, NT-proBNP trajectories provide reassurance when escalating disease-modifying therapies and signal when treatment adjustments are needed. [2,4] 

Q9. Is NT-proBNP useful across different heart failure phenotypes?

Yes. NT-proBNP is informative in both heart failure with reduced and preserved ejection fraction. Although levels may be lower in certain populations, such as obese patients, elevated NT-proBNP consistently identifies higher-risk individuals and retains prognostic value across phenotypes. [1] 

Q10. What is the overarching message regarding NT-proBNP in AHF management?NT-proBNP should be viewed not as a single diagnostic test, but as a longitudinal clinical tool. When used systematically, it improves early diagnosis, refines risk stratification, guides therapy during hospitalisation, and informs post-discharge management, ultimately supporting better outcomes in acute heart failure. [4]